14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CRMD vs DRTS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alpha Tau Medical Ltd. (DRTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas DRTS carries 43.3/100 (HOLD) at $12.03 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. DRTS 43.3/100 HOLD) and 1.22β · 103% Vol risk profile, whereas DRTS leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile DRTS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs DRTS. Trailing 12-month operating profitability (CRMD 41.0% vs DRTS 0.0%) and valuation multiples (CRMD 29.5x vs DRTS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRMD vs DRTS Key Questions & Quantitative Answers
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alpha Tau Medical Ltd. (DRTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin), whereas DRTS carries 43.3/100 (HOLD) at $12.03 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. DRTS 43.3/100 HOLD) and 1.22β · 103% Vol risk profile, whereas DRTS leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8); meanwhile DRTS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DRTS leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with DRTS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRMD generates $1.01B in USD-normalized revenue versus N/A for DRTS. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($469M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRTS.
CRMD screens cheaper on headline valuation multiples. CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas DRTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus DRTS (-141.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CRMD carries 53.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk). By comparison, DRTS carries 118.4% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 1.47x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.